Quantcast

Increased hexosaminidase activity in antipsychotic-induced extrapyramidal side effects: possible association with higher occurrence in bipolar disorder patients.

Research paper by Zeliha Z Tunca, Halil H Resmi, H Asuman HA Ozkara, Gönenc G Ciliv, Basak B Celtikci, Koksal K Alptekin, Aysegul A Ozerdem, Berna Kivircik BK Akdede, Burak B Baykara, Bilge B Birsoy, Gul G Ergor

Indexed on: 26 Apr '08Published on: 26 Apr '08Published in: Progress in Neuro-Psychopharmacology & Biological Psychiatry



Abstract

Dystonic movements and Parkinsonism are frequently seen in gangliosidoses and these conditions have been reported to modify dopaminergic plasticity. We investigated whether the activity of hexosaminidase, a type-two ganglioside (GM2) degrading enzyme, correlates with drug-induced extrapyramidal system (EPS) side effects in psychiatric patients. We compared hexosaminidase activity in the lymphocytes of 29 EPS-positive patients, 13 EPS-negative patients, and 30 healthy volunteers. The activities of A and B isoforms of hexosaminidase were higher in EPS-positive patients than EPS-negative patients and healthy controls. Multivariate analysis suggested an interaction with increased B isoform activity and EPS side effects in female bipolar disorder patients. Higher levels of hexosaminidase enzyme activity may explain the frequent occurrence of antipsychotic-induced extrapyramidal side effects in mood disorder patients.